No coin nor oath required. For personal study only.
The increase in the net loss primarily reflects clinical trial costs incurred for the company's lead product, Surfaxin, currently in three Phase III trials and one Phase II trial. Selected updates on the company's progress in 1Q 2002 are included in the report. Revenues from collaborative agreements were $237,000 during 1Q 2002 ($456,000 in 1Q 2001). Expenses due to research and development were $2.605 M ($1.762 M in 1Q 2001). Discovery Laboratories Inc is a speciality pharmaceutical company leveraging its platform technology in humanized lung surfactants to develop potential novel respiratory therapies and pulmonary drug delivery products. Condensed consolidated statements of operations of the company for three months ended Mar 2001 and 2002, and condensed consolidated balance sheets data as of 31 Dec 2001 and 31 Mar 2002 are provided in two tables.
π SIMILAR VOLUMES
loss of $19.366 M (operating loss of $16.45
## To Russia with love: it's the multinationals' new darling The Russian economy now appears to have stabilised, Consumer spending has increased so rapidly during 2000-2002 that not only are retail majors being attracted to the country but is also making it the fastest growing market for many of th
biological agriculture (BioAg) delivered higher growth than expected. Biopharmaceutical ingredients (BPI) experienced a decline of 1% in LCY. Financial results data are tabulated and graphically illustrated.